Selank: uses, evidence and status | Inside Your Peptides

compound file

The answer, first. A synthetic analogue of the immune peptide tuftsin, developed in Russia and used there as a prescription anxiolytic since the 2000s. The strongest evidence is for generalised anxiety disorder, graded C — small or open-label human only.

One Russian trial gave selank to 30 patients with generalised anxiety or neurasthenia, and medazepam to 32 ¹.

It reported similar anxiolytic effect on Hamilton and Zung scales ¹. No placebo arm, no blinding. The rest of what it is sold for — anxiety in healthy adults, alcohol withdrawal symptoms — grade D or E: animal or mechanism data with no controlled human outcome.

What it is used for

Every use graded on its own evidence, not the compound as a whole. 4 outcomes, ranked by what the human record supports.

#outcome · human · animal · gradewhat the best evidence actually shows

01Generalised anxiety disorderone open comparison, n=62 · rat anxiety modelsgrade COne Russian trial gave selank to 30 patients with generalised anxiety or neurasthenia, and medazepam to 32 ¹. It reported similar anxiolytic effect on Hamilton and Zung scales ¹. No placebo arm, no blinding.

02Asthenia alongside anxietysame trial, secondary reading · none for this outcomegrade CThe same trial reported antiasthenic and psychostimulant effects that medazepam did not produce ¹. A second Russian report tracked serum cytokine shifts over 14 days of selank in the same patient group ².

03Anxiety in healthy adultsimaging endpoints only · rat elevated plus mazegrade DA placebo-controlled study in 52 healthy participants found selank and semax changed resting connectivity between right amygdala and right temporal cortex ³. That is an imaging endpoint, not an anxiety measure.

04Alcohol withdrawal symptomsno trial · rat and mouse withdrawal modelsgrade DRat only. A single 0.3 mg/kg intraperitoneal dose removed withdrawal anxiety and prevented mechanical allodynia in alcohol-preferring rats without changing ethanol intake ⁹. No human withdrawal trial exists.

gradewhat it means

ARegulatory approval, or multiple adequately-powered trials agreeing with each other

BAt least one well-powered human randomised trial, with the direction replicated

CSmall or open-label human trials only

DAnimal or mechanism data only, with no controlled human outcome

EA claim the human trials have already killed

How it works

The proposed mechanism, in three steps. A mechanism is a reason to run a trial, never a substitute for one.

1targetA tuftsin analogue. No selank receptor has been identified. The working model is allosteric modulation of the GABA system ⁴.

2signalIn rat frontal cortex, 300 mcg/kg changed expression of 45 of 84 neurotransmission genes at 1 hour, correlating with GABA itself ⁴.

3effectHuman work measured a rise in serum leu-enkephalin half-life during treatment, correlating with anxiety scores ¹.

What it does not do

Claims the current record does not support. Worth knowing before you set expectations.

not supported by the evidence

A benzodiazepine without the downsides. One open trial matched it against medazepam on anxiety scales ¹. A pharmacology review classes it among poorly studied Russian drugs ⁵.
Russian registration equals replicated evidence. No blinded placebo-controlled selank trial for anxiety has been published in any language. Registration and replication are different things.
Measured nootropic effect in healthy people. The only controlled healthy-volunteer study measured brain connectivity, not cognition ³. No trial has tested memory or attention against placebo.

How it is used

What published protocols administered, and what the community reports doing. Descriptive on both counts, and never a recommendation.

routeIntranasal in Russian practice and in the imaging studies. Rodent work compares intranasal against intraperitoneal delivery.

formatAqueous nasal solution in Russian practice, lyophilised powder on the research market.

published dosesThe Russian anxiety trial dosed selank for 14 days against medazepam and reports duration rather than a milligram schedule ¹². Rodent studies use 300 mcg/kg ⁴. No human dose-ranging study has been published.

human pharmacokineticsNo human pharmacokinetic data published. Rat tracer work found intranasal delivery best for reaching the central nervous system ⁸.

reported conventionsAs reported on nootropics forums and vendor threads, 2014 to 2026: intranasal doses in the low hundreds of micrograms, once or twice a day. Taken on the day it is wanted rather than on a schedule, in runs of two to three weeks. Convention, not guidance.

commonly paired withSemax

This site does not publish protocols to follow. The doses above are what studies administered or what users report, stated as facts about the literature and the market. How protocols are structured, mixing and storage and the reconstitution calculator cover the arithmetic.

What to expect

Where a trial measured it, the trial. Where only the community reports it, that is said out loud.

onsetThe Russian trial ran 14 days before its endpoint ¹. The imaging study saw a connectivity change 5 to 20 minutes after a dose ³. No trial has measured how fast an anxiety change appears.

most common reportAs reported: a mild same-day calming without sedation, and nothing at all for a large share of users.

adverse effectsThe Russian trial publishes no adverse-event table ¹. No placebo-controlled safety data exist at any dose. As reported: nasal irritation, and drowsiness at higher volumes.

the stop signalThe published protocol ends at 14 days ¹. As reported: users stop when a run ends rather than on a signal, and restart situationally.

Approval and status

What regulators and sport bodies have actually said, separately from what the evidence shows.

approvalRegistered as a medicine in Russia. No approval in the US, EU or UK.

FDANot FDA-approved and not an approved US drug product. Sold on the research market.

sport [WADA]Not named on the Prohibited List. Russian registration bears on S0.

sold asresearch chemical

Covered in depth

These reports grade Selank at length and carry their own verified reference lists.

The State of Peptides, 2026: What They Are, Who Is Fighting Over Them, and What Each One Can Prove

Seventeen compounds, one ladder, no generosity. Two hold an FDA approval for what they are sold to do, seven grade D, and the thing everyone called a legalisation in April 2026 was the opposite.

Check the vial

The grade above describes a molecule studied under controlled conditions. It says nothing about the powder in a particular vial.

That gap is the one part of this market a reader can actually close. How to read a certificate of analysis covers the five measures in five minutes, and the 2026 audit grades vendors on the documents they publish against a rubric printed in full.

Questions we get

What is Selank used for?

In Russia it is prescribed as an anxiolytic for generalised anxiety disorder and neurasthenia, and that is where its one human trial sits ¹.

Elsewhere it is bought for situational calm and focus. The trial compared it against medazepam in 62 patients with no placebo arm and no blinding, so the size of any real effect is unknown.

How is Selank used?

Descriptively. Russian practice gives it as nasal drops. The published anxiety trial reports a 14-day course but no milligram schedule ¹, which is a genuine gap in the record.

Rodent studies use 300 mcg/kg intraperitoneally ⁴. Tracer work in rats found intranasal delivery reached the central nervous system best of the routes compared ⁸.

How long does Selank take to work?

The trial read its anxiety endpoint at 14 days ¹. The only acute human measurement is imaging.

A resting connectivity change between right amygdala and right temporal cortex, 5 to 20 minutes after a dose, in 52 healthy participants ³. That is a brain signal, not a mood outcome. No trial has timed a felt effect.

Is Selank an approved drug?

It is registered as a medicine in Russia and nowhere else, and it is sold in the West as a research chemical. Registration in one jurisdiction is not a replicated trial base.

A 2021 clinical pharmacology review lists selank among poorly studied Russian drugs ⁵. On our index it is graded human [ru] on clinical evidence and moderate on community adoption.

How do I know what is actually in a vial of Selank?

You do not, unless a certificate of analysis for that specific lot says so. A certificate worth trusting covers five measures: identity, purity, measured net content, endotoxin and a microbial screen.

It names the lab that ran them and carries an accession number you can verify with that lab. Most certificates on this market cover one to three of the five. Purity alone is one number, not a quality programme.

References

Zozulia AA, Neznamov GG, Siuniakov TS, et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID 18454096
Uchakina ON, Uchakin PN, Miasoedov NF, et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID 18577961
Panikratova YR, Lebedeva IS, Sokolov OY, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020. PMID 32342318
Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016. PMID 26924987
Doyno CR, White CM. Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. J Clin Pharmacol. 2021. PMID 34396551
Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017. PMID 28280289
Kolik LG, Nadorova AV, Antipova TA, et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bull Exp Biol Med. 2019. PMID 31625062
Ashmarin IP, Zolotarev YA, Andreeva LA, et al. [A comparative analysis of distribution of glyprolines administered by various routes]. Bioorg Khim. 2008. PMID 18695718
Kolik LG, Nadorova AV, Kozlovskaya MM. Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation. Bull Exp Biol Med. 2014. PMID 24913576
Zolotarev YA, Dadayan AK, Dolotov OV, et al. [Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation]. Bioorg Khim. 2006. PMID 16637290

Inside Your Peptides is published by the owners of the next lab, a vendor graded elsewhere on this site. We sell nothing here, and this page carries no vendor link. Grades follow the published criteria in our editorial policy — never referral terms. Research and education only. Not medical advice.